Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:IOVA NASDAQ:IPSC NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.35+1.3%$6.08$3.49▼$8.40$1.55B0.624.37 million shs2.93 million shsIOVAIovance Biotherapeutics$3.70+4.5%$3.65$1.66▼$5.63$1.58B0.6914.98 million shs10.58 million shsIPSCCentury Therapeutics$2.27+0.9%$2.30$0.44▼$3.04$405.80M1.55687,571 shs499,144 shsTSHATaysha Gene Therapies$5.54+0.9%$5.38$2.25▼$7.30$1.58B1.252.39 million shs2.21 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+2.96%-1.72%-0.48%-6.97%+50.00%IOVAIovance Biotherapeutics+2.31%-3.28%-6.35%+24.21%+85.34%IPSCCentury Therapeutics+6.13%-1.32%-3.85%+5.14%+275.00%TSHATaysha Gene Therapies+5.98%-17.69%-15.02%+14.61%+87.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.35+1.3%$6.08$3.49▼$8.40$1.55B0.624.37 million shs2.93 million shsIOVAIovance Biotherapeutics$3.70+4.5%$3.65$1.66▼$5.63$1.58B0.6914.98 million shs10.58 million shsIPSCCentury Therapeutics$2.27+0.9%$2.30$0.44▼$3.04$405.80M1.55687,571 shs499,144 shsTSHATaysha Gene Therapies$5.54+0.9%$5.38$2.25▼$7.30$1.58B1.252.39 million shs2.21 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+2.96%-1.72%-0.48%-6.97%+50.00%IOVAIovance Biotherapeutics+2.31%-3.28%-6.35%+24.21%+85.34%IPSCCentury Therapeutics+6.13%-1.32%-3.85%+5.14%+275.00%TSHATaysha Gene Therapies+5.98%-17.69%-15.02%+14.61%+87.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$15.70147.24% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.43127.80% UpsideIPSCCentury Therapeutics 2.33Hold$3.6761.53% UpsideTSHATaysha Gene Therapies 3.00Buy$11.64110.04% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, ARDX, TSHA, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.004/21/2026IPSCCentury Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $5.004/20/2026ARDXArdelyx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.004/6/2026IOVAIovance Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026IPSCCentury Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026TSHATaysha Gene Therapies Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.003/27/2026TSHATaysha Gene Therapies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026IOVAIovance Biotherapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/25/2026TSHATaysha Gene Therapies Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/19/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M3.85N/AN/A$0.60 per share10.58IOVAIovance Biotherapeutics$263.50M6.27N/AN/A$1.62 per share2.28IPSCCentury Therapeutics$109.16M3.75$0.01 per share169.17$1.47 per share1.54TSHATaysha Gene Therapies$9.77M162.95N/AN/A$0.74 per share7.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A12.70N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)IPSCCentury Therapeutics-$9.58M-$1.14N/AN/AN/AN/A-49.89%-37.42%5/21/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%N/ALatest IPSC, ARDX, TSHA, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026IPSCCentury Therapeutics-$0.15N/AN/AN/A$2.87 millionN/A5/13/2026Q1 2026IPSCCentury Therapeutics-$0.15-$0.11+$0.04-$0.11$2.87 millionN/A5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 million3/12/2026Q4 2025IPSCCentury Therapeutics-$0.29-$0.25+$0.04-$0.25($0.08) millionN/A2/24/2026Q4 2025IOVAIovance Biotherapeutics-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28IOVAIovance BiotherapeuticsN/A3.603.15IPSCCentury TherapeuticsN/A10.2510.25TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%IOVAIovance Biotherapeutics77.03%IPSCCentury Therapeutics50.20%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%IOVAIovance Biotherapeutics7.80%IPSCCentury Therapeutics4.37%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableIPSCCentury Therapeutics170180.35 million172.47 millionOptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableIPSC, ARDX, TSHA, and IOVA HeadlinesRecent News About These CompaniesNeedham ups Taysha target on ‘derisking’ TSHA-102 newsMay 15, 2026 | msn.comTaysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026May 14, 2026 | finance.yahoo.comCanaccord Keeps Buy Rating on Taysha (TSHA) After Q1 HighlightsMay 11, 2026 | insidermonkey.comTaysha Gene Therapies Ramps Up Ahead of TSHA-102 BLAMay 10, 2026 | tipranks.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by BrokeragesMay 10, 2026 | marketbeat.comAssessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent VolatilityMay 9, 2026 | finance.yahoo.comTaysha Gene Therapies, Inc. Q1 2026 Earnings Call SummaryMay 9, 2026 | finance.yahoo.comTaysha Gene Therapies (NASDAQ:TSHA) Lowered to "Sell" Rating by Wall Street ZenMay 9, 2026 | marketbeat.comTaysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysisMay 7, 2026 | seekingalpha.comTaysha Gene Therapies Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsMay 6, 2026 | marketbeat.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Here's What HappenedMay 5, 2026 | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on WednesdayMay 2, 2026 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comTaysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay RevealedApril 22, 2026 | quiverquant.comQTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Should You Buy?April 22, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, ARDX, TSHA, and IOVA Company DescriptionsArdelyx NASDAQ:ARDX$6.35 +0.08 (+1.28%) Closing price 04:00 PM EasternExtended Trading$6.35 +0.00 (+0.05%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Iovance Biotherapeutics NASDAQ:IOVA$3.70 +0.16 (+4.52%) Closing price 04:00 PM EasternExtended Trading$3.68 -0.02 (-0.43%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Century Therapeutics NASDAQ:IPSC$2.27 +0.02 (+0.89%) Closing price 04:00 PM EasternExtended Trading$2.24 -0.03 (-1.32%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Taysha Gene Therapies NASDAQ:TSHA$5.54 +0.05 (+0.91%) Closing price 04:00 PM EasternExtended Trading$5.70 +0.17 (+2.98%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
